• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Oppenheimer initiated coverage on Praxis Precision Medicines with a new price target

    8/5/24 6:37:58 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email
    Oppenheimer initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $134.00
    Get the next $PRAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRAX

    DatePrice TargetRatingAnalyst
    6/2/2025$97.00Outperform
    Oppenheimer
    5/7/2025$80.00Buy
    Chardan Capital Markets
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    2/11/2025$111.00Buy
    Deutsche Bank
    8/5/2024$134.00Outperform
    Oppenheimer
    6/24/2024$145.00Buy
    Needham
    6/18/2024$155.00Buy
    Guggenheim
    5/1/2024$117.00Outperform
    Robert W. Baird
    More analyst ratings

    $PRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Adage Capital Management, L.P.

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    10/17/25 4:10:45 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Dean J exercised 12,251 shares at a strike of $39.51, increasing direct ownership by 245% to 17,251 units (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    9/25/25 4:40:48 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Adage Capital Management, L.P. claimed ownership of 2,374,085 units of Title of Security (SEC Form 3)

    3 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    8/19/25 4:10:13 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Praxis Precision Medicines with a new price target

    Oppenheimer resumed coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $97.00

    6/2/25 8:54:06 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Praxis Precision Medicines with a new price target

    Chardan Capital Markets initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $80.00

    5/7/25 8:38:09 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Praxis Precision Medicines with a new price target

    H.C. Wainwright reiterated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $105.00 from $120.00 previously

    3/3/25 7:53:12 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    SEC Filings

    View All

    Praxis Precision Medicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

    10/21/25 8:02:31 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Praxis Precision Medicines Inc.

    424B5 - Praxis Precision Medicines, Inc. (0001689548) (Filer)

    10/16/25 5:08:02 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

    10/16/25 7:58:26 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    10/10/23 7:41:39 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

    BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,025,480 shares of its common stock at a public offering price per share of $157.00 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 318,470 shares of common stock at a purchase price of $156.9999 per pre-funded warrant, which equals the public offering price per share of the common sto

    10/16/25 11:45:19 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines, Inc. Announces Proposed Public Offering

    BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or

    10/16/25 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

    Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 points (p<0.0001)  All key secondary endpoints in Study 1 - rate of disease improvement over 12 weeks, PGI-C and CGI-S - were also statistically significant (p<0.001) Study 2 met its pre-specified primary endpoint, with patients showing superior maintenance of effect while on ulixacaltamide versus placebo during the randomized-withdrawal phase (p=0.0369) The first key secondary endpoint in Study 2 - rate of disease improvement during the randomized-withdrawal phase - also demon

    10/16/25 7:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Leadership Updates

    Live Leadership Updates

    View All

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

    PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

    8/8/22 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

    BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence

    5/23/22 9:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Announces Management Team Appointments

    BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Megan Sniecinski as chief business officer and provided key updates on members of the executive leadership team. Praxis has promoted Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D., to chief technical operations officer. In addition, chief scientific officer and co-founder, Steven Petrou, Ph.D., has decided to fully dedicate his time to Praxis upon stepping

    12/2/21 7:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Financials

    Live finance-specific insights

    View All

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxi

    8/4/25 8:30:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

    Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment Rapid and sustained response, with over 54% of patients achieving 50% response in the first week Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitati

    8/4/25 8:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

    BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report topline results from the RADIANT trial of vormatrigine and its financial results from the second quarter ended June 30, 2025, before the financial markets open on Monday, August 4, 2025. The Company will host a live webcast the same morning at 8:30am ET, which can be accessed by visiting this registration link. This live webcast will also be available through th

    7/29/25 8:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:46:12 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care